Continuing Medical Education
Accreditation Statement
- Disclosure Index
- Claiming credit for the AACR Virtual Meeting: COVID-19 and Cancer
- Commercial Support
The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.
Credit Designation Statement
AACR has designated this internet live activity for a maximum of 27.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.
Claiming CME Credit
Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)TM for this live continuing medical education activity must complete the online CME Request for Credit Survey by Friday, March 19, 2021. Certificates will only be issued to those who complete the survey. Your CME certificate will be sent to you via email after the completion of the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 27.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
To receive ABIM MOC, participants must request MOC in the CME Request for Credit Survey and complete all questions. Once these steps are completed, AACR will submit your completion information via the ACCME’s Program and Activity Reporting System for the purpose of granting MOC points.
Statement of Educational Need, Target Audience, and Learning Objectives
The coronavirus pandemic has entered a “third wave” with many countries experiencing record numbers of confirmed cases and corresponding increases in hospitalizations and patient deaths. The impact on the worldwide healthcare infrastructure has been well documented – from lack of supplies, hospital space, staffing shortages, mental strain on the existing workforce, and financial strain at medical institutions and governments.
Despite rapid advances in testing capacities, repurposing of existing drugs, and promising vaccine development made since the SARS-CoV2 virus first appeared in late 2019, the pandemic continues to impact daily lives around the globe with no end in sight. Many regions of North America and Europe are returning to restrictions not seen since the height of the pandemic in early 2020.
Practicing oncologists, clinical investigators, translational and basic researchers, must continue to educate themselves through conferences like this to understand the biology of the virus, successful clinical strategies implemented to improve survival rates and continue cancer care, new diagnostic and technological tools, the impact of health inequities and disparities, and risk factors and comorbidities that potentially have long-term consequences for cancer patients.
This program will gather thought leaders across a range of topic areas that have practice implications for clinicians, both within oncology and across other medical specialties. The conference will present emerging data on continuity of care, drug repurposing, early detection and testing, and health disparities and inequities which continue to be of vital importance to physicians and medical professionals.
After participating in this CME activity, physicians should be able to:
- Articulate how outcomes may be impacted by socioeconomic, ethnic, gender, and other health disparities.
- Distinguish the differences between different vaccine strategies being pursued and their potential for global impact on the pandemic.
- Explain how certain risk factors and comorbidities increase adverse outcomes for certain cancer patients.
- Identify successful drug repurposing strategies being used for the treatment of patients with COVID-19 and limitations of those strategies.
- Provide an overview of successful telehealth strategies implemented during the COVID-19 pandemic and assess how those may impact care in the future.
Disclosure Statement
It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available in the Program/Proceedings of this conference.
Acknowledgment of Financial or Other Support
The AACR gratefully acknowledges the following commercial supporters:
Supporters
Janssen Research and Development, LLC
Novartis
professional EDUCATION GRANTS
AbbVie
Astellas
AstraZeneca
Daiichi Sankyo, Inc.
Questions about CME?
Please contact the Office of CME at (215) 440-9300 or [email protected].